LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.

AstraZeneca PLC (LSE: AZN) Latest News

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

I asked ChatGPT for the best UK stocks for me to buy for 2025. Here are 5 names it gave me

Edward Sheldon turned to artificial intelligence in his quest to find the best UK stocks for him to buy for…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

If the market shut down for 10 years, I’d be happy to hold these 2 FTSE 100 shares

Our writer reveals a pair of FTSE 100 shares that he reckons are well set up to deliver strong returns…

Read more »

piggy bank, searching with binoculars
Investing Articles

Analysts are saying the AstraZeneca share price looks cheap despite China turmoil

The AstraZeneca share price could be considerably undervalued according to analysts. Dr James Fox takes a closer look at the…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing For Beginners

Something big just happened in the UK stock market

Jon Smith talks through some data he's just found, which could indicate a positive change of sentiment for the UK…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

5 simple steps for targeting a £1,000,000 SIPP

Through regular contributions and careful monitoring, investors can target a seven-figure long-term SIPP to improve their retirement quality of life.

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Down 20% in 14 weeks, is AstraZeneca’s share price now too big a bargain for me to miss?

AstraZeneca’s share price has fallen a long way on an investigation surrounding its Chinese business. So, do the shares look…

Read more »

Engineer Project Manager Talks With Scientist working on Computer
Investing Articles

Where might the AstraZeneca share price go in 2025? Here’s what the experts forecast

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the…

Read more »

piggy bank, searching with binoculars
Growth Shares

Directors at this FTSE 100 company just bought over £2m worth of shares

Shares in this FTSE 100 pharma company have plummeted in recent months. And company insiders are betting on a potential…

Read more »

Golden hand holding Number 2 foil balloon.
Investing Articles

2 top shares I’ve bought for my Stocks and Shares ISA in November

This writer reveals a pair of fast-growing businesses that he's recently added to his Stocks and Shares ISA for the…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

What on earth is going on with the AstraZeneca share price?

The AstraZeneca share price has fallen 30% from its peak in August. Dr James Fox explains what’s going on with…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Growth Shares

The AstraZeneca share price just fell 8.4% in a day. Is it time to consider buying?

The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

If I’d put £25,000 into the FTSE 350 at the start of 2024, here’s how much I’d have today!

Many FTSE shares have rebounded this year as interest rates look set to keep heading lower and market appetite for…

Read more »